Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

from the Department of Defense to advance a next generation mammalian cell culture expression system for our recombinant chemical nerve agent bioscavenger program."

Conference Call and Webcast InformationPharmAthene management will be hosting a conference call to discuss the Company's third quarter 2011 financial and operating results.  The call is scheduled to begin at 8:30 a.m. Eastern Time on Wednesday, November 9, 2011 and is expected to last approximately 30 minutes. The dial-in number within the United States is 888-268-4176.  The dial-in number for international callers is 617-597-5493.  The participant passcode is 54772588.

A replay of the conference call will be available beginning at approximately 11:30 a.m. Eastern Time on November 9, 2011 until approximately 11:30 a.m. Eastern Time on December 9, 2011.  The dial-in number to access the replay from within the United States is 888-286-8010.   For international callers, the dial-in number is 617-801-6888.  The participant passcode is 88200860.

The conference call will also be webcast and can be accessed from the Company's website at www.PharmAthene.com.  A link to the webcast may be found under the Investor Relations section of the website.  

About PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

  • In addition, pu
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    7. PharmAthene Completes $6.5 Million Registered Direct Offering
    8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/1/2015)... 2015 Market Publishers Ltd and ... market research promotion on Internet. MarketPublishers.com is now ... out by DataGroup Booksellers. , Natalie Aster, Assistant ... commented on the recent partnership agreement as follows: ... our team of publishers. Since 1974, the company ...
    (Date:2/27/2015)... Feb. 27, 2015 A paper published ... rare-diseases portfolio " in Science Translational Medicine, ... technique to reduce the risk associated with investing ... unlock new levels of funding for developing so-called ... a unique collaboration between scientists at the National ...
    (Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
    (Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
    Breaking Biology Technology:Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
    ... Calif., Nov. 16 Fate Therapeutics, Inc. ... Series B financing led by OVP Venture Partners. Joining ... corporate investors, including Astellas Venture Management, Genzyme Ventures and a ... Company,s Series A financing, ARCH Venture Partners, Polaris Venture Partners ...
    ... , BEIJING, Nov. 15 ... developer and provider of vaccines, announced today its unaudited financial results ... Financial Highlights , Sales for the third quarter ... increased 40% to $47.8 million Operating income for the third ...
    ... German . , The performance of ... to the ongoing miniaturization of the utilized components. However, ... structures are simply made smaller and reach the nanometer ... approach: the engineering of functional structures with the smallest ...
    Cached Biology Technology:Fate Therapeutics Closes $30 Million Series B Financing 2Fate Therapeutics Closes $30 Million Series B Financing 3Fate Therapeutics Closes $30 Million Series B Financing 4Sinovac Reports Unaudited Third Quarter 2009 Financial Results 2Sinovac Reports Unaudited Third Quarter 2009 Financial Results 3Sinovac Reports Unaudited Third Quarter 2009 Financial Results 4Sinovac Reports Unaudited Third Quarter 2009 Financial Results 5Sinovac Reports Unaudited Third Quarter 2009 Financial Results 6Sinovac Reports Unaudited Third Quarter 2009 Financial Results 7Sinovac Reports Unaudited Third Quarter 2009 Financial Results 8Sinovac Reports Unaudited Third Quarter 2009 Financial Results 9Sinovac Reports Unaudited Third Quarter 2009 Financial Results 10Sinovac Reports Unaudited Third Quarter 2009 Financial Results 11Sinovac Reports Unaudited Third Quarter 2009 Financial Results 12Sinovac Reports Unaudited Third Quarter 2009 Financial Results 13Sinovac Reports Unaudited Third Quarter 2009 Financial Results 14Sinovac Reports Unaudited Third Quarter 2009 Financial Results 15In touch with molecules 2
    (Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
    (Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
    (Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
    Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
    ... -- The sequences of nonsense DNA that interrupt genes ... genomes than previously thought, according to a recent Science ... Hampshire biologists. Their study of the model organism ... to demonstrate the colonization of a single lineage by ...
    ... animals you can think of and you probably come up ... catfish? A new study by University of Michigan ... possibly more than 1,600 species of catfish may be venomous---far ... paper published online Dec. 4 in the open access journal ...
    ... more sensitive to atmospheric carbon dioxide in the long ... published in Nature Geoscience . ... conditions, including global temperatures, may need to be adjusted ... affecting water supplies for cities and farms; leading to ...
    Cached Biology News:Introns: A mystery renewed 2Introns: A mystery renewed 3Introns: A mystery renewed 4 Killer catfish? Venomous species surprisingly common, study finds 2Climate projections underestimate CO2 impact 2
    ... shakers have the durability to ... 3-high, and the uniformity and ... shake" applications. Heavily built ... our stackers are designed for ...
    ... Acquire images with any of UVP's Doc-It ... the Doc-It 1D Analysis software onto your ... image analysis functions and enhancement tools. Doc-It ... band finding algorithms for quick and accurate ...
    CQCS kit for first KR 4i , (first unit)....
    ... Multidrop Combi is a new generation dispenser ... dispensing with the proven performance of the existing ... cover large volume area starting from 500 nl ... the range. ,It is optimized for ...
    Biology Products: